D2Discovery
1 known investors
Data2Discovery builds a knowledge graph and data science software platform that integrates and analyzes large, complex, heterogeneous datasets to surface insights in fields such as drug discovery, disaster medicine, and food science. It serves pharmaceutical, biotech, research, and government organizations, with applications including drug repurposing, toxicology, and phenotypic analysis.
Founders & leadership
DW
David WildπPresident & Founder
Investors Β· 1
Non-dilutive funding Β· 2 SBIR/STTR awards
Federal grants β no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Science Foundation | Phase II | 2017 | $750K |
| National Science Foundation | Phase I | 2016 | $150K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts β non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does D2Discovery do?
- Data2Discovery builds a knowledge graph and data science software platform that integrates and analyzes large, complex, heterogeneous datasets to surface insights in fields such as drug discovery, disaster medicine, and food science. It serves pharmaceutical, biotech, research, and government organizations, with applications including drug repurposing, toxicology, and phenotypic analysis.
- Who founded D2Discovery?
- D2Discovery was founded by David Wild.
- Who are D2Discovery's investors?
- D2Discovery's investors include IU Ventures.